In the realm of targeted therapies for lung cancer, the debate between Alectinib and Lorlatinib continues to stir discussions among oncologists and researchers. Alectinib, a drug approved for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), has been a game-changer in improving patient outcomes. Meanwhile, Lorlatinib, another ALK inhibitor, has...

In the realm of targeted cancer therapies, alectinib and lorlatinib stand as prominent choices for treating specific types of lung cancer. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, and lorlatinib, another ALK inhibitor, have garnered significant attention for their efficacy and potential side effects. This article delves into a comparative analysis of alectinib and lorlatinib,...